Navigation Links
Dendreon Announces Presentation of PROVENGE Data at the American Urological Association Annual Meeting
Date:5/31/2010

SEATTLE and SAN FRANCISCO, May 31 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced the presentation of safety data from the integrated analysis of four randomized PROVENGE® (sipuleucel-T) clinical trials of an autologous cellular immunotherapy in prostate cancer at the 105th Annual Scientific Meeting of the American Urological Association (AUA) in San Francisco.

"The approval of PROVENGE provides us with an important new, front-line option for men with asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer," said Simon Hall, M.D., director of the Barbara and Maurice Deane Prostate Health and Research Center at Mount Sinai Medical Center.  

The analysis includes data from four randomized trials in patients with either metastatic castrate resistant prostate cancer (Studies D9901, D9902A, IMPACT) or androgen dependent prostate cancer (Study  P-11) that were integrated to examine the safety profile of PROVENGE across the four studies. The safety evaluation of PROVENGE was based on 601 prostate cancer patients in four randomized clinical trials who underwent at least one leukapheresis procedure. The abstract presented was a poster presentation by Dr. Hall, titled "Integrated safety results from 4 randomized, double-blind, placebo-controlled studies of sipuleucel-T (abstract #1000875)."

PROVENGE is the first autologous cellular immunotherapy to be approved by the U.S. Food and Drug Administration for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractor
'/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Presents Updated IMPACT Results Confirming PROVENGE Improves Overall Survival in Patients With Metastatic Castrate-Resistant Prostate Cancer
2. Dendreon Reports Fourth Quarter and 2009 Year End Financial Results
3. Dendreon Announces Election of Ian Clark and Pedro Granadillo to Board of Directors
4. Dendreon Reports PROVENGE Regulatory and Commercialization Progress and Future Pipeline Plans at Analyst Event
5. Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia
6. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
7. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
8. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
9. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
10. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
11. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 ... 4,396.20, down 0.52%, the Dow Jones Industrial Average finished the ... at 1,964.68, down 0.41%. The losses were broad based as ... The S&P 500 Health Care Sector Index ended the day ... in the last one month. Investor-Edge has initiated coverage on ...
(Date:7/11/2014)... SAN DIEGO , July 11, 2014 ... Therapies Corp. ("Biotie") to end the option held by ... to commence further development of NRL-1 (intranasal diazepam) for ... seizures. Over the past year, Biotie has ... Neurelis in preparation for the pivotal clinical work required ...
(Date:7/10/2014)... -- Integrated Silicon Solution, Inc. (Nasdaq: ISSI ... solutions, today announced that it will host its earnings ... a.m. Pacific Time (10:00 a.m. Eastern Time) to discuss ... quarter ended June 30, 2014. To access ... a.m. Pacific time on July 24, 2014.  The participant ...
Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3
... PRINCETON, N.J., April 5, 2012  In conjunction with its first quarter 2012 ... 2012), Covance Inc. (NYSE: CVD ) is pleased to invite ... broadcast live over the Internet on Thursday, May 3, 2012 at 9:00 ... First Quarter 2012 Earnings Webcast and Slide Presentation , , , ...
... SPRING, Md., April 4, 2012   Sunpeaks Ventures, ... or "Sunpeaks Ventures") and its wholly owned subsidiary ... announce that HDS has signed a marketing and ... Partners and Skyrock ("AACSA Partners/Skyrock") to distribute and ...
Cached Medicine Technology:Sunpeaks Ventures Announces Agreement with Asian American Convenience Store Association Partners to Sell Clotamin in 1,200 Stores 2Sunpeaks Ventures Announces Agreement with Asian American Convenience Store Association Partners to Sell Clotamin in 1,200 Stores 3
(Date:7/13/2014)... 13, 2014 Advanced boilers are ... least amount of fossil fuels, produce high-capacity power, ... to increased global warming and climate change concerns, ... reduce harmful gas emissions and pollutants coming from ... in the global advance boilers market., The global ...
(Date:7/13/2014)... HealthDay Reporter FRIDAY, July 11, 2014 ... people with diabetes is being developed to measure sugar levels ... Scientists at Brown University in Providence, R.I., created the ... light, metal and a special enzyme that changes color when ... to prick their fingers to draw blood to check their ...
(Date:7/13/2014)... Max International has recently ... be the featured guest at its Charity Exhibition and ... Attendees will learn about Max’s health products and ... basketball games and perform in a 3 point shoot-out. ... and energy-boosting supplements , has recently announced former NBA ...
(Date:7/13/2014)... July 13, 2014 A decreased ability to ... impairment and Alzheimer,s disease, while examinations of the ... protein associated with Alzheimer,s, in the brain, according ... today at the Alzheimer,s Association International Conference 2014 ... the studies, the decreased ability to identify odors ...
(Date:7/13/2014)... ECS is being founded by Seattle ... a special needs child, I have become keenly aware ... contemporary special education resources and evidence-based instruction. Emerald City ... families in the Seattle metro area that are looking ... We welcome the opportunity to serve our community and ...
Breaking Medicine News(10 mins):Health News:North America Advanced Boilers Market is Expected to Reach $518.7billion by 2019 - New Report by MicroMarket Monitor 2Health News:North America Advanced Boilers Market is Expected to Reach $518.7billion by 2019 - New Report by MicroMarket Monitor 3Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 2Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 3Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 3Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 4Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7Health News:New Private School, Emerald City School, Founded in Downtown Seattle Now Accepting 1st to 6th Grade Students Who Learn Differently 2
... Global Provider of both Medical Travel ... Assistance and Risk Management Services, BALTIMORE, May 15 ... the acquisition of ASI Group (formerly Air,Security International). In operation ... independently owned provider of global travel,security and medical assistance in ...
... Inc. (Amex: NEP ),announced today financial results for the ... -- Increased product revenues by 31% to $387,000. ... OLpur(TM) H2H(TM) Hemodiafiltration Module and OLpur(TM) ... VP of Marketing and Business Development -- Hired Gerald ...
... Health Solutions, Corp.,("SXC" or the "Company") (NASDAQ: SXCI ... services, announces that Mark Thierer,President and COO and Jeff ... Capital Markets 12th Annual Spring Investor Conference at the ... on Thursday, May 29,2008 at 10:30 am Eastern Time., ...
... YORK, May 15 Mergent, Inc., administrator for ... for the,HealthShares(TM) Exchange Traded Funds, today announced the ... Monday May 19, 2008: Genzyme,Corporation (Nasdaq: GENZ ... ) in,the HealthShares(TM) Composite Index, Coloplast AS (OMX ...
... they,re twice as likely to be injured, so prevention strategies ... Stroke patients have a high risk of falling after they ... The University of Auckland researchers added that prevention programs may ... stroke fall almost twice as often as people who haven,t ...
... May 15 A federal judge last,night ruled against Johnson ... Cross from using the Red Cross emblem on first aid ... judge,s ruling,represents a complete vindication of the right of the ... of its emblem in the sale of,products related to its ...
Cached Medicine News:Health News:MEDEX Global Group Acquires ASI Group 2Health News:MEDEX Global Group Acquires ASI Group 3Health News:Nephros Reports 2008 First Quarter Financial Results 2Health News:Nephros Reports 2008 First Quarter Financial Results 3Health News:Nephros Reports 2008 First Quarter Financial Results 4Health News:Nephros Reports 2008 First Quarter Financial Results 5Health News:Mergent, Inc. Announces Changes to the HealthShares(TM) Composite Index, Dermatology and Wound Care Index and Orthopedic Repair Index - Correction 2Health News:Mergent, Inc. Announces Changes to the HealthShares(TM) Composite Index, Dermatology and Wound Care Index and Orthopedic Repair Index - Correction 3Health News:Stroke Patients at High Risk for Falls 2Health News:American Red Cross Vindicated in J&J Lawsuit 2Health News:American Red Cross Vindicated in J&J Lawsuit 3
... Capture vital signs faster, easier, and ... LXi, the latest innovation in multi-parameter ... Spot LXi, you get more parameters ... flexibility to customize it to meet ...
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Medicine Products: